Literature DB >> 7561215

Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis.

J F Arevalo1, C Gonzalez, E V Capparelli, L S Kirsch, R F Garcia, J I Quiceno, J D Connor, J Gambertoglio, G Bergeron-Lynn, W R Freeman.   

Abstract

This study evaluated intravitreous and plasma ganciclovir and foscarnet concentrations after intravenous administration in AIDS patients with cytomegalovirus (CMV) retinitis and retinal detachment. Undiluted vitreous samples were prospectively obtained from 60 eyes (52 patients) at the time of pars plana vitrectomy. Thirty-three plasma samples (from 27 patients in the initial group of 52) were obtained simultaneously during surgery on 33 eyes. High-pressure liquid chromatography showed the mean vitreous ganciclovir concentrations in patients on induction and maintenance therapy were, respectively, 4.74 +/- 1.49 microM (n = 24) and 3.29 +/- 1.84 microM (n = 30; P = .005). Simultaneous plasma ganciclovir concentrations were less than the vitreous concentrations in 78% of the patients. The mean intravitreous foscarnet concentrations in patients receiving induction dosages were 189 +/- 177 microM (n = 5) versus 163 +/- 167 microM (n = 4; P > .20) for those receiving maintenance therapy. The foscarnet vitreous plasma concentration ratio averaged 1.43. Current drugs and doses for CMV retinitis result in borderline or progressively subtherapeutic concentrations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561215     DOI: 10.1093/infdis/172.4.951

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits.

Authors:  L F López-Cortés; R Ruiz-Valderas; M J Lucero-Muñoz; E Cordero; M T Pastor-Ramos; J Marquez
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

3.  Drug-resistant herpesviruses: should we look for them?

Authors:  G Boivin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

Review 4.  Comparative tolerability of therapies for cytomegalovirus retinitis.

Authors:  S Walmsley; A Tseng
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

5.  The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments.

Authors:  A Tseng; M Foisy
Journal:  Can J Infect Dis       Date:  1996-05

Review 6.  Antimicrobial guide to posterior segment infections.

Authors:  Tapan P Patel; David N Zacks; Vaidehi S Dedania
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-06       Impact factor: 3.117

7.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26

8.  Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture.

Authors:  Daniel F Martin
Journal:  Am J Ophthalmol       Date:  2018-01-12       Impact factor: 5.258

9.  Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.

Authors:  Jo Seddon; Sanjay Bhagani
Journal:  HIV AIDS (Auckl)       Date:  2011-04-04

10.  NEOVASCULAR COMPLICATIONS FROM CYTOMEGALOVIRUS NECROTIZING RETINOPATHY IN PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Authors:  Ze Long; Jing Hou; Heng Miao
Journal:  Retina       Date:  2021-07-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.